Literature DB >> 36118538

Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study.

Robert P Baughman1,2, Rohit Gupta3, Marc A Judson4, Elyse E Lower1, Surinder S Birring5, Jeffrey Stewart3, Rebecca Reeves1, Athol U Wells6.   

Abstract

Entities:  

Year:  2022        PMID： 36118538      PMCID： PMC9437762          DOI： 10.36141/svdld.v39i2.12940

Source DB:  PubMed          Journal:  Sarcoidosis Vasc Diffuse Lung Dis        ISSN： 1124-0490            Impact factor:   1.803


× No keyword cloud information.
  16 in total

1.  Stage IV sarcoidosis: comparison of survival with the general population and causes of death.

Authors:  A Nardi; P-Y Brillet; P Letoumelin; F Girard; M Brauner; Y Uzunhan; J-M Naccache; D Valeyre; H Nunes
Journal:  Eur Respir J       Date:  2011-11-10       Impact factor: 16.671

2.  Interpretative strategies for lung function tests.

Authors:  R Pellegrino; G Viegi; V Brusasco; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N MacIntyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

3.  Six-minute walk test and health status assessment in sarcoidosis.

Authors:  Robert P Baughman; Brian K Sparkman; Elyse E Lower
Journal:  Chest       Date:  2007-07       Impact factor: 9.410

4.  Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry.

Authors:  Robert P Baughman; Oksana A Shlobin; Athol U Wells; Esam H Alhamad; Daniel A Culver; Joseph Barney; Francis C Cordova; Eva M Carmona; Mary Beth Scholand; Marlies Wijsenbeek; Sivagini Ganesh; Surinder S Birring; Vasilis Kouranos; Lanier O'Hare; Joanne M Baran; Joseph G Cal; Elyse E Lower; Peter J Engel; Steven D Nathan
Journal:  Respir Med       Date:  2018-05-05       Impact factor: 3.415

5.  An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study.

Authors:  Simon Lf Walsh; Athol U Wells; Nicola Sverzellati; Gregory J Keir; Lucio Calandriello; Katerina M Antoniou; Susan J Copley; Anand Devaraj; Toby M Maher; Elizabetta Renzoni; Andrew G Nicholson; David M Hansell
Journal:  Lancet Respir Med       Date:  2014-01-15       Impact factor: 30.700

6.  Predictors of mortality in fibrosing pulmonary sarcoidosis.

Authors:  Florence Jeny; Yurdagül Uzunhan; Maxime Lacroix; Thomas Gille; Pierre-Yves Brillet; Annelyse Nardi; Diane Bouvry; Carole Planès; Hilario Nunes; Dominique Valeyre
Journal:  Respir Med       Date:  2020-05-12       Impact factor: 3.415

Review 7.  ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders.

Authors:  G W Hunninghake; U Costabel; M Ando; R Baughman; J F Cordier; R du Bois; A Eklund; M Kitaichi; J Lynch; G Rizzato; C Rose; O Selroos; G Semenzato; O P Sharma
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  1999-09       Impact factor: 0.670

8.  Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography.

Authors:  Athol U Wells; Sujal R Desai; Michael B Rubens; Nicole S L Goh; Derek Cramer; Andrew G Nicholson; Thomas V Colby; Roland M du Bois; David M Hansell
Journal:  Am J Respir Crit Care Med       Date:  2003-04-01       Impact factor: 21.405

9.  Sarcoidosis-related mortality in the United States from 1988 to 2007.

Authors:  Jeffrey J Swigris; Amy L Olson; Tristan J Huie; Evans R Fernandez-Perez; Joshua Solomon; David Sprunger; Kevin K Brown
Journal:  Am J Respir Crit Care Med       Date:  2011-02-17       Impact factor: 21.405

10.  Measuring fatigue in sarcoidosis: the Fatigue Assessment Scale (FAS).

Authors:  Jolanda De Vries; Helen Michielsen; Guus L Van Heck; Marjolein Drent
Journal:  Br J Health Psychol       Date:  2004-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.